Immunologic Gene Signature Analysis Correlates Myeloid Cells and M2 Macrophages with Time to Trabectedin Failure in Sarcoma Patients

SIMPLE SUMMARY: Trabectedin is an FDA-approved chemotherapy with demonstrated benefit for some sarcoma subtypes, particularly in the metastatic setting. Although some patients receiving trabectedin have only modest benefit, other patients are exceptional responders. While several mechanisms of actio...

Descripción completa

Detalles Bibliográficos
Autores principales: Schroeder, Brett A., Zhang, Yuzheng, Smythe, Kimberly S., Desai, Parth, Thomas, Anish, Viveiros, Pedro, Alexiev, Borislav A., Obeidin, Farres, Chen, Eleanor Y., Cranmer, Lee D., Wagner, Michael J., Jones, Robin L., Campbell, Jean S., Pierce, Robert H., He, Qianchuan, Pollack, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909887/
https://www.ncbi.nlm.nih.gov/pubmed/35267598
http://dx.doi.org/10.3390/cancers14051290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909887/
https://www.ncbi.nlm.nih.gov/pubmed/35267598
http://dx.doi.org/10.3390/cancers14051290

Ejemplares similares